LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

Search

CureVac NV

Open

3.68 7.92

Overview

Share price change

24h

Current

Min

3.43

Max

3.75

Key metrics

By Trading Economics

Income

-409M

-39M

Sales

-479M

14M

P/E

Sector Avg

4.469

56.602

EPS

-0.156

Profit margin

-266.508

Employees

825

EBITDA

-410M

-35M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+104.15% upside

Dividends

By Dow Jones

Next Earnings

22 May 2025

Market Stats

By TradingEconomics

Market Cap

79M

815M

Previous open

-4.24

Previous close

3.68

Technical Score

By Trading Central

Confidence

Bullish Evidence

CureVac NV Chart

Past performance is not a reliable indicator of future results.

Related News

3 Jul 2024, 09:14 UTC

Acquisitions, Mergers, Takeovers

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

3 Jul 2024, 14:18 UTC

Acquisitions, Mergers, Takeovers

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 Jul 2024, 09:38 UTC

Market Talk

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Peer Comparison

Price change

CureVac NV Forecast

Price Target

By TipRanks

104.15% upside

12 Months Forecast

Average 6.88 USD  104.15%

High 12 USD

Low 2.5 USD

Based on 4 Wall Street analysts offering 12 month price targets forCureVac NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

2

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

3.47 / 3.755Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.